1.AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma.
Jung Hee KWON ; Keun Soo AHN ; Young Ho MOON ; Jin Young PARK ; Hee Jung WANG ; Kwan Yong CHOI ; Gundo KIM ; Jae Won JOH ; Kyeong Geun LEE ; Koo Jeong KANG
Journal of Korean Medical Science 2015;30(9):1253-1259
Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the non-cirrhotic HCC patients (P=0.015) and also in tumor tissues irrespective of tumor stage (P<0.001) or BCLC stage (P<0.001). High mRNA levels of AROS were statistically significantly associated with tumor stage (P<0.001), BCLC stage (P=0.007), alpha fetoprotein (AFP) level (P=0.013), microvascular invasion (P=0.001), tumor size (P=0.036), and portal vein invasion (P=0.005). Kaplan-Meir curve analysis demonstrated that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both the short-term (P<0.001) and long-term (P=0.005) compared to those with low AROS. Cox regression analysis demonstrated that AROS is a significant predictor for DFS along with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, which are the known prognostic factors. In conclusion, AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.
Adult
;
Age Distribution
;
Aged
;
Biomarkers, Tumor/*metabolism
;
Carcinoma, Hepatocellular/*epidemiology/*metabolism/pathology
;
Disease-Free Survival
;
Female
;
Humans
;
Liver Cirrhosis/epidemiology/metabolism/pathology
;
Liver Neoplasms/*epidemiology/*metabolism/pathology
;
Male
;
Middle Aged
;
Neoplasm Invasiveness
;
Nuclear Proteins/*metabolism
;
Prevalence
;
Reproducibility of Results
;
Republic of Korea/epidemiology
;
Risk Factors
;
Sensitivity and Specificity
;
Sex Distribution
;
Transcription Factors/*metabolism
;
Young Adult
2.The Effect of Intraoperative and Postoperative Music on Patients of Regional Anesthesia.
Man Jo KIM ; Dong Jun LEE ; Mi Ae HAN ; Kyoung Ho HA ; Moon Chul KIM ; Kang Hee JOH
Korean Journal of Anesthesiology 2006;50(4):444-448
BACKGROUND: Music influences the body and mental well-being of humans. Almost all patients undergoing surgery experience perioperative anxiety. This study was designed to determine the effect of music during surgery and the post-operation period under regional anesthesia on the level of anxiety, relaxation and fatigue. METHODS: Sixty-four patients who underwent orthopedic surgery under regional anesthesia were randomly assigned to Group 1 (listening to music) and Group 2 (no music). The premedication and anesthesia were standardized for both groups. The level of anxiety, fatigue and psychological well-being were examined as outcome variables. RESULTS: The level of anxiety and psychological well-being was significantly lower (anxiety: P = 0.012, psychological well-being: P = 0.006) in Group 1 than in Group 2. The level of fatigue was similar in both groups. CONCLUSIONS: The results suggested that music might be effective in reducing the level of intra and post-operative anxiety and improving the psychological well-being of patients undergoing surgery under regional anesthesia.
Anesthesia
;
Anesthesia, Conduction*
;
Anxiety
;
Fatigue
;
Humans
;
Music*
;
Orthopedics
;
Premedication
;
Relaxation
3.The comparison of monitored anesthesia care with dexmedetomidine and spinal anesthesia during varicose vein surgery.
Eun Jin MOON ; Ki Woon KANG ; Jun Young CHUNG ; Jong Man KANG ; Je Hoon PARK ; Jin Hyun JOH ; Ho Chul PARK ; Jae Woo YI
Annals of Surgical Treatment and Research 2014;87(5):245-252
PURPOSE: The purpose of this study was to investigate the effectiveness and safety of monitored anesthesia care (MAC) using dexmedetomidine for its sedative and analgesic effect during varicose vein surgery. METHODS: Forty-two patients, who underwent varicose vein surgery, were divided into the MAC group (n = 20) or the spinal anesthesia group (n = 22) for randomized clinical trial. In the MAC group, dexmedetomidine was administered by a loading dose of 1 microg/kg for 10 minutes, followed by a maintenance infusion of 0.2-1.0 microg/kg/hr. Ketamine was used for intermittent injection. In the spinal anesthesia group, midazolam was used for sedation. Intraoperative vital signs, the number of adverse events, and the satisfaction of patients and surgeons concerning the anesthetic condition were compared between the two groups. RESULTS: Systolic blood pressure was intraoperatively significantly different over time between the two groups. The groups had statistical differences in the change in heart rate with regard to time. In the postanesthetic care unit, patients and surgeons in the MAC group had a lower satisfaction score, compared to patients and surgeons in the spinal anesthesia group. However, in the recovery period, patients had a positive perception concerning MAC anesthesia. In addition, without significant adverse events, the MAC group had a shorter time to possible ambulation, which indicated an early recovery. CONCLUSION: We believe that MAC using dexmedetomidine in combination with ketamine may be an alternative anesthetic technique for varicose vein surgery with regard to a patient's preference and medical condition.
Anesthesia*
;
Anesthesia, Spinal*
;
Blood Pressure
;
Dexmedetomidine*
;
Heart Rate
;
Humans
;
Ketamine
;
Midazolam
;
Varicose Veins*
;
Vital Signs
;
Walking
4.Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
Hae-Young LEE ; Juhee AHN ; Juhong PARK ; Chang Kyung KANG ; Sung-Ho WON ; Dong Wook KIM ; Jong-Heon PARK ; Ki-Hyun CHUNG ; Joon-Sung JOH ; JI Hwan BANG ; Cheong Hee KANG ; Myoung-don OH ; Wook Bum PYUN ; ;
The Korean Journal of Internal Medicine 2021;36(3):617-628
Background/Aims:
Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective role. This study aimed to compare the association of ARBs and ACEIs with COVID-19-related mortality.
Methods:
All patients with COVID-19 in Korea between January 19 and April 16, 2020 were enrolled. The association of ARBs and ACEIs with mortality within 60 days were evaluated. A comparison of hazard ratio (HR) was performed between COVID-19 patients and a retrospective cohort of pneumonia patients hospitalized in 2019 in Korea.
Results:
Among 10,448 COVID-19 patients, ARBs and ACEIs were prescribed in 1,231 (11.7%) and 57 (0.6%) patients, respectively. After adjusting for age, sex, and history of comorbidities, the ARB group showed neutral association (HR, 1.034; 95% CI, 0.765 to 1.399; p = 0.8270) and the ACEI groups showed no significant associations likely owing to the small population size (HR, 0.736; 95% CI, 0.314 to 1.726; p = 0.4810). When comparing HR between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia in 2019, the trend of ACEIs showed similar benefits, whereas the protective effect of ARBs observed in the retrospective cohort was absent in COVID-19 patients. Meta-analyses showed significant positive correlation with survival of ACEIs, whereas a neutral association between ARBs and mortality.
Conclusions
Although ARBs or ACEIs were not associated with fatal outcomes, potential beneficial effects of ARBs observed in pneumonia were attenuated in COVID-19.
5.Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
Hae-Young LEE ; Juhee AHN ; Juhong PARK ; Chang Kyung KANG ; Sung-Ho WON ; Dong Wook KIM ; Jong-Heon PARK ; Ki-Hyun CHUNG ; Joon-Sung JOH ; JI Hwan BANG ; Cheong Hee KANG ; Myoung-don OH ; Wook Bum PYUN ; ;
The Korean Journal of Internal Medicine 2021;36(3):617-628
Background/Aims:
Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective role. This study aimed to compare the association of ARBs and ACEIs with COVID-19-related mortality.
Methods:
All patients with COVID-19 in Korea between January 19 and April 16, 2020 were enrolled. The association of ARBs and ACEIs with mortality within 60 days were evaluated. A comparison of hazard ratio (HR) was performed between COVID-19 patients and a retrospective cohort of pneumonia patients hospitalized in 2019 in Korea.
Results:
Among 10,448 COVID-19 patients, ARBs and ACEIs were prescribed in 1,231 (11.7%) and 57 (0.6%) patients, respectively. After adjusting for age, sex, and history of comorbidities, the ARB group showed neutral association (HR, 1.034; 95% CI, 0.765 to 1.399; p = 0.8270) and the ACEI groups showed no significant associations likely owing to the small population size (HR, 0.736; 95% CI, 0.314 to 1.726; p = 0.4810). When comparing HR between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia in 2019, the trend of ACEIs showed similar benefits, whereas the protective effect of ARBs observed in the retrospective cohort was absent in COVID-19 patients. Meta-analyses showed significant positive correlation with survival of ACEIs, whereas a neutral association between ARBs and mortality.
Conclusions
Although ARBs or ACEIs were not associated with fatal outcomes, potential beneficial effects of ARBs observed in pneumonia were attenuated in COVID-19.
6.Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea.
Won Suk CHOI ; Cheol In KANG ; Yonjae KIM ; Jae Phil CHOI ; Joon Sung JOH ; Hyoung Shik SHIN ; Gayeon KIM ; Kyong Ran PECK ; Doo Ryeon CHUNG ; Hye Ok KIM ; Sook Hee SONG ; Yang Ree KIM ; Kyung Mok SOHN ; Younghee JUNG ; Ji Hwan BANG ; Nam Joong KIM ; Kkot Sil LEE ; Hye Won JEONG ; Ji Young RHEE ; Eu Suk KIM ; Heungjeong WOO ; Won Sup OH ; Kyungmin HUH ; Young Hyun LEE ; Joon Young SONG ; Jacob LEE ; Chang Seop LEE ; Baek Nam KIM ; Young Hwa CHOI ; Su Jin JEONG ; Jin Soo LEE ; Ji Hyun YOON ; Yu Mi WI ; Mi Kyong JOUNG ; Seong Yeon PARK ; Sun Hee LEE ; Sook In JUNG ; Shin Woo KIM ; Jae Hoon LEE ; Hyuck LEE ; Hyun Kyun KI ; Yeon Sook KIM
Infection and Chemotherapy 2016;48(2):118-126
BACKGROUND: From May to July 2015, the Republic of Korea experienced the largest outbreak of Middle East respiratory syndrome (MERS) outside the Arabian Peninsula. A total of 186 patients, including 36 deaths, had been diagnosed with MERS-coronavirus (MERS-CoV) infection as of September 30th, 2015. MATERIALS AND METHODS: We obtained information of patients who were confirmed to have MERS-CoV infection. MERS-CoV infection was diagnosed using real-time reverse-transcriptase polymerase chain reaction assay. RESULTS: The median age of the patients was 55 years (range, 16 to 86). A total of 55.4% of the patients had one or more coexisting medical conditions. The most common symptom was fever (95.2%). At admission, leukopenia (42.6%), thrombocytopenia (46.6%), and elevation of aspartate aminotransferase (42.7%) were observed. Pneumonia was detected in 68.3% of patients at admission and developed in 80.8% during the disease course. Antiviral agents were used for 74.7% of patients. Mechanical ventilation, extracorporeal membrane oxygenation, and convalescent serum were employed for 24.5%, 7.1%, and 3.8% of patients, respectively. Older age, presence of coexisting medical conditions including diabetes or chronic lung disease, presence of dyspnea, hypotension, and leukocytosis at admission, and the use of mechanical ventilation were revealed to be independent predictors of death. CONCLUSION: The clinical features of MERS-CoV infection in the Republic of Korea were similar to those of previous outbreaks in the Middle East. However, the overall mortality rate (20.4%) was lower than that in previous reports. Enhanced surveillance and active management of patients during the outbreak may have resulted in improved outcomes.
Antiviral Agents
;
Aspartate Aminotransferases
;
Coronavirus Infections*
;
Disease Outbreaks
;
Dyspnea
;
Extracorporeal Membrane Oxygenation
;
Fever
;
Humans
;
Hypotension
;
Leukocytosis
;
Leukopenia
;
Lung Diseases
;
Middle East Respiratory Syndrome Coronavirus
;
Middle East*
;
Mortality
;
Pneumonia
;
Polymerase Chain Reaction
;
Republic of Korea*
;
Respiration, Artificial
;
Thrombocytopenia